menopause%20-and-%20hormone%20therapy
MENOPAUSE & HORMONE THERAPY
Spontaneous/Natural menopause is the final menstrual period confirmed after 12 consecutive months of amenorrhea with no pathological cause.
Induced menopause is the permanent cessation of menstruation after bilateral oophorectomy (ie surgical menopause) or iatrogenic ablation of ovarian function (eg pelvic radiation therapy, chemotherapy).
Perimenopause/Menopause transition/Climacteric is the duration when menstrual cycle & endocrine changes occur a few years before and 12 months after the final menstrual period resulting from natural menopause.
Premature menopause is menopause before 40 years of age whether natural or induced while early menopause is spontaneous or induced menopause that occurs before the average age of natural menopause at 51 years or under 45 years of age.

Menopause%20-and-%20hormone%20therapy Management

Follow Up

  • Schedule follow-up visit within a few months (eg 3 months) of starting menopausal hormone therapy (MHT)
    • Monitor compliance, response and side effects especially bleeding
    • Counsel on expected bleeding patterns and need for regular breast self-examination
    • Adjust MHT if required
  • Patient should be evaluated yearly thereafter
    • Review risks versus benefits
    • Urinalysis and blood pressure (BP) at each visit
    • Cervical smears for all women with uterus
    • Every 2 years: Perform physical exam, lipid profile, liver function tests (LFTs), fasting glucose and mammogram if indicated
    • Perform bone mineral density (BMD) as required
  • If women experience recurrence of hot flushes after stopping ET, non-hormonal agents may be tried; if symptoms persist, MHT may be resumed at the lowest effective dose or transdermal therapy may be considered in select patients with periodic reevaluation 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 2 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.